
Nyxoah SA (NYXH) Stock Forecast & Price Target
Nyxoah SA (NYXH) Analyst Ratings
Bulls say
Nyxoah is showing strong progress in its U.S. commercialization, with a successful launch, positive value analysis committee results, and continued growth in sales representatives and trained surgeons. The completion of its ACCCESS study in late June/early July 2026 could be a major catalyst for the company. Additionally, their recent combination financing of €77M, including participation from major players in the industry, shows confidence in the company's future success. However, slower initial revenue ramp and recalibration of financial models lead to a revised price target of $9.00 based on ~6x 2027 revenue estimate.
Bears say
Nyxoah is facing multiple risks including challenges with its roll-out against a market leader, potential cash flow issues, and regulatory risks associated with its ACCCESS study. Despite positive updates and a solid foundation for commercialization, these risks could hinder investor confidence and limit the company's success. Repeating orders from the 4Q25 success may provide a boost in the short term, but long-term growth and sustainability will heavily depend on the company's ability to overcome these obstacles.
This aggregate rating is based on analysts' research of Nyxoah SA and is not a guaranteed prediction by Public.com or investment advice.
Nyxoah SA (NYXH) Analyst Forecast & Price Prediction
Start investing in Nyxoah SA (NYXH)
Order type
Buy in
Order amount
Est. shares
0 shares